Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Three Years, Seven Acquisitions Later, Cardinal Health Has More Plans In China

This article was originally published in The Pink Sheet Daily

Executive Summary

U.S. distributor Cardinal Health goes full speed ahead in China. It has bought local players to tap into the regional market, doubled direct-to-patient pharmacies, and provided pharmacy management services to large hospitals among endeavors in the past three and a half years with more to come.

You may also be interested in...



Challenges, Opportunities For Cardinal In China Policy Change

Major US pharma distributor Cardinal Health is further expanding its regional presence in China, with the country’s rapidly changing operating environment presenting opportunities and challenges.

Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?

SHANGHAI - In what some are calling a transformational event for the China pharma industry, Cardinal Health announced Nov. 29 that it has closed a deal to acquire local private distributor Zuellig Pharma China (Yong Yu in Chinese) for $470 million

Medtechs Must Reflect On China Localization Policies As VBP Expands

China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS077321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel